On the other hand, though recent research demonstrated that advanced NSCLC patients with exon 19 deletion might have longer PFS compared to those with L858 mutation after first-line EGFR-TKIs [32, 62], the reason for the observed difference remained inconclusive. This evidence concerns the gene EGFR and non-small cell lung carcinoma.